AVEO Pharmaceuticals, Inc. (AVEO) , a stock from Biotechnology Industry, has a value of $2.18 per share, noted a price change of -0.46% in recent trade close. The price to sales ratio is 36.70. The lower price P/S ratio indicates attractive the investment. A low P/S can also be effective in valuing growth stocks that have suffered a temporary setback. A low P/S ratio may indicate possible undervaluation, while a ratio that is significantly above the average may suggest overvaluation. Abbreviated as the P/S ratio or PSR, this ratio is also known as a “sales multiple” or “revenue multiple.”
Annual earnings per share (EPS) growth noted at 25.30% in past 5 Years and The company is estimating to achieve earnings per share (EPS) growth of -58.10% in this year and the earnings per share (EPS) growth expected to be -66.70% in the next year.
Analysts mean Recommendation on a stock is noted at 2.00. Analyst Recommendation is an outlook of a stock-market analyst on a stock. Rating Scale: 1.0 represent “Strong Buy” and 2.0 signify “Buy” 3.0 while shows “Hold”. 4.0 display “Sell” and 5.0 reveal “Strong Sell” rating.
The performance for week is -6.64% and the performance for quarter is at -29.68%. The performance for month is -21.30% and the performance for half year is -29.45%. Its monthly volatility value of 5.37% and volatility for the week is valued at 4.68%. The performance for Year to Date (YTD) is -21.86%.
53.20% shares of the company possessed by Institutional Investors. The net percent change held by Institutional Investors has seen a change of 0.33% in last three month period. Insiders own 0.63% of AVEO Pharmaceuticals, Inc. (AVEO) shares.
A ROI of 129.70% for the company evaluates and compares the efficiency of the various numbers of investments relative to the cost of investments.